132 related articles for article (PubMed ID: 9211441)
1. The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
Marchesi C; Ampollini P; Signifredi R; Maggini C
Neuropsychobiology; 1997; 36(1):25-31. PubMed ID: 9211441
[TBL] [Abstract][Full Text] [Related]
2. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.
Mavissakalian MR; Perel JM; Talbott-Green M; Sloan C
Biol Psychiatry; 1998 Jun; 43(11):848-54. PubMed ID: 9611676
[TBL] [Abstract][Full Text] [Related]
3. The use of the Panic and Agoraphobia Scale in a clinical trial.
Bandelow B; Brunner E; Broocks A; Beinroth D; Hajak G; Pralle L; Rüther E
Psychiatry Res; 1998 Jan; 77(1):43-9. PubMed ID: 10710174
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up after a drug trial for panic disorder.
Katschnig H; Amering M; Stolk JM; Klerman GL; Ballenger JC; Briggs A; Buller R; Cassano G; Garvey M; Roth M
Br J Psychiatry; 1995 Oct; 167(4):487-94. PubMed ID: 8829718
[TBL] [Abstract][Full Text] [Related]
5. Specific side effects of long-term imipramine management of panic disorder.
Mavissakalian M; Perel J; Guo S
J Clin Psychopharmacol; 2002 Apr; 22(2):155-61. PubMed ID: 11910260
[TBL] [Abstract][Full Text] [Related]
6. A 15-year follow-up study of patients with panic disorder.
Andersch S; Hetta J
Eur Psychiatry; 2003 Dec; 18(8):401-8. PubMed ID: 14680716
[TBL] [Abstract][Full Text] [Related]
7. 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia.
Mavissakalian MR; Perel JM
Ann Clin Psychiatry; 2001 Jun; 13(2):63-7. PubMed ID: 11534926
[TBL] [Abstract][Full Text] [Related]
8. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
Mavissakalian MR; Perel JM
Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
[TBL] [Abstract][Full Text] [Related]
9. Duration of imipramine therapy and relapse in panic disorder with agoraphobia.
Mavissakalian MR; Perel JM
J Clin Psychopharmacol; 2002 Jun; 22(3):294-9. PubMed ID: 12006900
[TBL] [Abstract][Full Text] [Related]
10. [Panic disorder and agoraphobia: what is effective?].
Bandelow B; Sievert K; Röthemeyer M; Hajak G; Broocks A; Rüther E
Fortschr Neurol Psychiatr; 1995 Nov; 63(11):451-64. PubMed ID: 8575719
[TBL] [Abstract][Full Text] [Related]
11. Predictors of outcome in panic disorder: a 5-year prospective follow-up study.
Scheibe G; Albus M
J Affect Disord; 1996 Nov; 41(2):111-6. PubMed ID: 8961038
[TBL] [Abstract][Full Text] [Related]
12. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants.
Toni C; Perugi G; Frare F; Mata B; Vitale B; Mengali F; Recchia M; Serra G; Akiskal HS
Pharmacopsychiatry; 2000 Jul; 33(4):121-31. PubMed ID: 10958260
[TBL] [Abstract][Full Text] [Related]
13. Imipramine vs. sertraline in panic disorder: 24-week treatment completers.
Mavissakalian MR
Ann Clin Psychiatry; 2003; 15(3-4):171-80. PubMed ID: 14971862
[TBL] [Abstract][Full Text] [Related]
14. Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.
Lepola UM; Rimón RH; Riekkinen PJ
Int Clin Psychopharmacol; 1993; 8(2):115-8. PubMed ID: 8345160
[TBL] [Abstract][Full Text] [Related]
15. A naturalistic study of imipramine in panic disorder and agoraphobia.
Aronson TA
Am J Psychiatry; 1987 Aug; 144(8):1014-9. PubMed ID: 3300374
[TBL] [Abstract][Full Text] [Related]
16. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
Mavissakalian MR; Perel JM
Arch Gen Psychiatry; 1999 Sep; 56(9):821-7. PubMed ID: 12884888
[TBL] [Abstract][Full Text] [Related]
17. Coping behavior in patients with panic disorder.
Yamada K; Fujii I; Akiyoshi J; Nagayama H
Psychiatry Clin Neurosci; 2004 Apr; 58(2):173-8. PubMed ID: 15009823
[TBL] [Abstract][Full Text] [Related]
18. Maintenance drug therapy of panic disorder.
Curtis GC; Massana J; Udina C; Ayuso JL; Cassano GB; Perugi G
J Psychiatr Res; 1993; 27 Suppl 1():127-42. PubMed ID: 8145175
[TBL] [Abstract][Full Text] [Related]
19. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?
Maier W; Roth SM; Argyle N; Buller R; Lavori P; Brandon S; Benkert O
Eur Arch Psychiatry Clin Neurosci; 1991; 241(3):151-8. PubMed ID: 1790160
[TBL] [Abstract][Full Text] [Related]
20. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study.
Noyes R; Garvey MJ; Cook BL; Samuelson L
J Clin Psychiatry; 1989 May; 50(5):163-9. PubMed ID: 2715139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
